Literature DB >> 31760491

Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme.

Riuko Ohashi1,2,3, Guido Martignoni4,5, Arndt Hartmann6, Anna Caliò4, Diego Segala5, Christine Stöhr6, Sven Wach7, Franziska Erlmeier6,8, Wilko Weichert8, Michael Autenrieth9, Peter Schraml2, Niels J Rupp2, Chisato Ohe10, Yoshiro Otsuki11, Takashi Kawasaki12, Hiroshi Kobayashi13, Kazuhiro Kobayashi14, Tatsuhiko Miyazaki14, Hiroyuki Shibuya15, Hiroyuki Usuda16, Hajime Umezu17, Fumiyoshi Fujishima18, Bungo Furusato19,20, Mitsumasa Osakabe21, Tamotsu Sugai21, Naoto Kuroda22, Toyonori Tsuzuki23, Yoji Nagashima24, Yoichi Ajioka1,3, Holger Moch25.   

Abstract

A histological grading system of chromophobe renal cell carcinoma (chRCC) is highly desirable to identify approximately 5-10% of tumors at risk for progression. Validation studies failed to demonstrate a correlation between the four-tiered WHO/ISUP grade and outcome. Previous proposals with three-tiered chromophobe grading systems could not be validated. In this study, the presence of sarcomatoid differentiation, necrosis, and mitosis was analyzed in a Swiss cohort (n = 42), an Italian cohort (n = 103), a German cohort (n = 54), a Japanese cohort (n = 119), and The Cancer Genome Atlas cohort (n = 64). All 3 histological parameters were significantly associated with shorter time to tumor progression and overall survival in univariate analysis. Interobserver variability for identification of these parameters was measured by Krippendorff's alpha coefficient and showed high concordance for the identification of sarcomatoid differentiation and tumor necrosis, but only low to medium concordance for the identification of mitosis. Therefore, we tested a two-tiered tumor grading system (low versus high grade) based only on the presence of sarcomatoid differentiation and/or necrosis finding in the combined cohorts (n = 382). pT stage, patient's age (> 65 vs ≤ 65), lymph node and/or distant metastasis, and the two-tiered grading system (low versus high grade) were significantly associated with overall survival and were independent prognostic parameters in multivariate analysis (Cox proportional hazard). This multi-institutional evaluation of prognostic parameters suggests tumor necrosis and sarcomatoid differentiation as reproducible components of a two-tiered chromophobe tumor grading system.

Entities:  

Keywords:  Chromophobe renal cell carcinoma; Kidney; Mitosis; Necrosis; Prognosis; Sarcomatoid differentiation; The Cancer Genome Atlas (TCGA); Tumor grade

Mesh:

Year:  2019        PMID: 31760491     DOI: 10.1007/s00428-019-02710-w

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  1 in total

1.  Chromophobe renal cell carcinoma of the kidney with neuroendocrine differentiation: A case report with review of literature.

Authors:  Ghadeer A Mokhtar; Reem Al-Zahrani
Journal:  Urol Ann       Date:  2015 Jul-Sep
  1 in total
  11 in total

Review 1.  [Oncocytic tumours of the kidney-new differential diagnoses].

Authors:  I Polifka; R Ohashi; H Moch
Journal:  Pathologe       Date:  2021-09-01       Impact factor: 1.011

Review 2.  [Characterization of different renal cell carcinoma entities].

Authors:  N J Rupp; H Moch
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

3.  HNF-1β as an immunohistochemical marker for distinguishing chromophobe renal cell carcinoma and hybrid oncocytic tumors from renal oncocytoma.

Authors:  Jiyeon An; Cheol Keun Park; Moonsik Kim; Jin Woo Joo; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2020-08-20       Impact factor: 4.064

Review 4.  Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.

Authors:  Alessia Cimadamore; Liang Cheng; Marina Scarpelli; Francesco Massari; Veronica Mollica; Matteo Santoni; Antonio Lopez-Beltran; Rodolfo Montironi; Holger Moch
Journal:  Transl Androl Urol       Date:  2021-03

5.  MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.

Authors:  Franziska Erlmeier; Na Sun; Jian Shen; Annette Feuchtinger; Achim Buck; Verena M Prade; Thomas Kunzke; Peter Schraml; Holger Moch; Michael Autenrieth; Wilko Weichert; Arndt Hartmann; Axel Walch
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

6.  The synergism of spatial metabolomics and morphometry improves machine learning-based renal tumour subtype classification.

Authors:  Verena M Prade; Na Sun; Jian Shen; Annette Feuchtinger; Thomas Kunzke; Achim Buck; Peter Schraml; Holger Moch; Kristina Schwamborn; Michael Autenrieth; Jürgen E Gschwend; Franziska Erlmeier; Arndt Hartmann; Axel Walch
Journal:  Clin Transl Med       Date:  2022-02

Review 7.  Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates.

Authors:  Reza Alaghehbandan; Christopher G Przybycin; Virginie Verkarre; Rohit Mehra
Journal:  Asian J Urol       Date:  2021-12-01

Review 8.  A Causal Framework for Making Individualized Treatment Decisions in Oncology.

Authors:  Pavlos Msaouel; Juhee Lee; Jose A Karam; Peter F Thall
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

9.  Development and Validation of a Competitive Risk Model in Elderly Patients With Chromophobe Cell Renal Carcinoma: A Population-Based Study.

Authors:  Jinkui Wang; Chenghao Zhanghuang; Xiaojun Tan; Tao Mi; Jiayan Liu; Liming Jin; Mujie Li; Zhaoxia Zhang; Dawei He
Journal:  Front Public Health       Date:  2022-02-22

10.  Small cell variant of chromophobe renal cell carcinoma: Clinicopathologic and molecular-genetic analysis of 10 cases.

Authors:  Joanna Rogala; Fumiyoshi Kojima; Reza Alaghehbandan; Nikola Ptakova; Ana Bravc; Stela Bulimbasic; Delia Perez Montiel; Maryna Slisarenko; Leila Ali; Levente Kuthi; Kristyna Pivovarcikova; Kvetoslava Michalova; Boris Bartovic; Adriena Bartos Vesela; Olga Dolejsova; Michal Michal; Ondrej Hes
Journal:  Bosn J Basic Med Sci       Date:  2022-07-29       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.